SECONDARY HYPERPARATHYROIDISM
Clinical trials for SECONDARY HYPERPARATHYROIDISM explained in plain language.
Never miss a new study
Get alerted when new SECONDARY HYPERPARATHYROIDISM trials appear
Sign up with your email to follow new studies for SECONDARY HYPERPARATHYROIDISM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for dialysis patients with hormone imbalance
Disease control CompletedThis study tested a new medicine called PLS240 in 412 adults with end-stage kidney disease on dialysis who also have overactive parathyroid glands (secondary hyperparathyroidism). The goal was to see if PLS240 can safely lower high parathyroid hormone levels better than a placebo…
Matched conditions: SECONDARY HYPERPARATHYROIDISM
Phase: PHASE3 • Sponsor: Pathalys Pharma • Aim: Disease control
Last updated May 17, 2026 03:55 UTC
-
New drug shows promise for dialysis patients with overactive parathyroid glands
Disease control CompletedThis study tested a new medicine called SHR6508 in 498 adults with kidney failure who were on dialysis and had secondary hyperparathyroidism (overactive parathyroid glands). The goal was to see if the drug could safely lower parathyroid hormone levels. Participants received eithe…
Matched conditions: SECONDARY HYPERPARATHYROIDISM
Phase: PHASE3 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New drug aims to tame parathyroid glands in dialysis patients
Disease control CompletedThis study tested a drug called PLS240 in 362 adults with end-stage kidney disease on dialysis who also have overactive parathyroid glands (secondary hyperparathyroidism). The goal was to see if PLS240 can safely lower high parathyroid hormone levels. Participants received either…
Matched conditions: SECONDARY HYPERPARATHYROIDISM
Phase: PHASE3 • Sponsor: Pathalys Pharma • Aim: Disease control
Last updated May 06, 2026 16:01 UTC
-
Drug tracking study in dialysis patients reveals how body eliminates treatment
Knowledge-focused CompletedThis study looked at how a drug called SHR6508 is processed and removed from the body in 5 Chinese adults on hemodialysis who have secondary hyperparathyroidism. Participants received a single dose of the drug, and researchers measured how much came out in urine and stool. The go…
Matched conditions: SECONDARY HYPERPARATHYROIDISM
Phase: PHASE1 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated May 17, 2026 04:10 UTC